(Q38481302)

3 September 2017

title

High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives (English)

1 reference

3 September 2017

1 reference

1 reference

angiogenesis inhibitor

1 reference

1 reference

9

Youngro Byun

1 reference

3 September 2017

Jin Woo Park

1

1 reference

3 September 2017

Ok Cheol Jeon

2

1 reference

3 September 2017

Sang Kyoon Kim

3

1 reference

3 September 2017

Taslim Ahmed Al-Hilal

4

1 reference

3 September 2017

Shun Ji Jin

5

1 reference

3 September 2017

Hyun Tae Moon

6

1 reference

3 September 2017

Sang Yoon Kim

8

1 reference

3 September 2017

Victor C. Yang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20869408

20 July 2024

language of work or name

English

0 references

publication date

30 September 2010

1 reference

full work available at URL

3 September 2017

https://api.elsevier.com/content/article/PII:S0168365910007790?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

https://api.elsevier.com/content/article/PII:S0168365910007790?httpAccept=text/plain

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Journal of Controlled Release

20 July 2024

published in

1 reference

3 September 2017

volume

148

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

317-326

1 reference

Antithrombotic therapy in gynecologic surgery and gynecologic oncology

3 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

20 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

20 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

20 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Heparin derivatives as angiogenesis inhibitors

20 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity

20 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Heparin octasaccharides inhibit angiogenesis in vivo.

20 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically

20 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist

20 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction

20 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Proteoglycans as modulators of growth factor activities

20 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor

20 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation

20 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization.

20 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Modulation of neovascularization and metastasis by species of heparin

20 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Mechanisms of heparin induced anti-cancer activity in experimental cancer models

20 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung

20 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis

20 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Antiangiogenic effect of bile acid acylated heparin derivative.

20 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis

20 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent

20 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Basic cholane derivatives. XI: Comparison between acid and basic derivatives

20 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro.

20 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Alkaline and smith degradation of oxidized dermatan sulphate-chondroitin sulphate copolymers

20 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.

20 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties

20 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Optical rotary dispersion of mucopolysaccharides. 3. Ultraviolet circular dichroism and conformational specificity in amide groups

20 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Viscosity at low shear and circular dichroism studies of heparin

20 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Variations in the Size and Sulfation of Heparin Modulate the Effect of Heparin on the Binding of VEGF165 to Its Receptors

20 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization

20 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis

20 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor

20 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant

20 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

Anticoagulant efficacy of solid oral formulations containing a new heparin derivative

20 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.JCONREL.2010.09.014

20 July 2024

Identifiers

1 reference

3 September 2017

1 reference